Baymatob is very happy to share that Lisa McIntyre and Tamara Mills have been appointed as non-executive directors of the company in March 2024.
“We are fortunate to have been able to attract two talented directors of the calibre of Lisa and Tamara. They have already contributed greatly to the Board given their vast industry knowledge and international experience. We further look forward to working with both Lisa and Tamara, as the company works towards its key clinical and commercial milestones”, said Tony Barclay, Board Chair.
We are proud to welcome two new directors with extensive experience across healthcare and medical device commercialisation. This adds to the vast existing expertise on the Board, and is an important step in supporting Baymatob’s continued growth in completing our Oli pivotal clinical trial, regulatory submissions and commercial activities.
Dr McIntyre has extensive knowledge in health and technology – with experience in strategy, finance, technology transformation and data analytics. She has a deep understanding of international markets and a reputation for insight, integrity and transparency.
Dr McIntyre is an experienced company director with a broad portfolio that spans the health care, insurance, technology and e-learning sectors. She is currently a non-executive director of Nanosonics Ltd, The University of Sydney, and Studiosity. Former appointments include the Garvan Institute of Medical Research, HCF, Genesis Care, and I-MED, amongst others.
Prior to her director roles, Dr McIntyre spent 20 years as a senior strategy partner with LEK Consulting. She helped develop the company’s US biotechnology advisory practice from three clients in the emerging sector to become the largest biotechnology practice in the US, providing strategic, commercial and operational advice to local and multinational companies in North America, Asia and Australia.
Tamara Mills is a seasoned leader in the medical technology industry with a proven track record in developing and commercializing innovative therapeutics and diagnostics. With over 15 years of experience in building and investing in life sciences and deep technology companies, Tamara has successfully led organizations from early clinical development through to FDA approval and commercialization.
Prior to returning to Australia, Tamara successfully built and directed the portfolio of pipeline assets across pharmaceuticals and medical devices for Jubilant DraxImage (JDI) in North America. As Director of JDI’s cardiovascular business, Tamara built the Diagnostic Cardiology business from the ground up, leading a complex drug-device technology to regulatory approval and commercialization. More recently, Tamara led Regulatory Affairs and Market Access for BWXT Technologies Medical Division , overseeing a portfolio of diagnostic and therapeutic products, and led strategic merger and acquisition diligence in the radiopharmaceutical sector at Predict Ltd.
Tamara holds several board and advisory roles in the life sciences sector and previously chaired the Health Policy, Regulatory, and Reimbursement committee for the North American Radiopharmaceutical Industry organization CORAR. Tamara currently oversees venture capital, private equity, and public equity investments in the life sciences and deep technology portfolio at Edale Capital.
Tamara holds a Masters in Business Administration, Masters in Health Economics, a Degree in Nuclear Medicine, a qualification in New Ventures Leadership from the Massachusetts Institute of Technology, and is a Graduate of the Australian Institute of Company Directors.